COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia말레이시아에서 BNT162b2 백신을 접종한 의료 종사자의 COVID-19 획기적인 감염 및 체액성 면역 반응Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] 95% CI affected age Anti-S1 Anti-spike antibody Antibody Response antibody titres association Asymptomatic Asymptomatic individuals blood sample Blood samples BNT162b2 booster vaccination breakthrough Breakthrough infection breakthrough infections collected COVID-19 COVID-19 infection delta variant detectable domain geometric mean geometric mean titre GMT HCWs healthcare healthcare worker Healthcare workers humoral humoral immune response Humoral immunity IgG IgG assay individual individuals Infection investigated Malaysia not different notable outcome Participants prospective cohort study Protein response significantly significantly higher Support symptomatic the antibody response vaccination Vaccine vaccine doses vaccine. waned was measured [DOI] 10.1080/22221751.2022.2065936 PMC 바로가기 [Article Type] Article
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection3회분의 BNT162b2 백신 또는 BA.1 감염에 의한 Omicron 하위 계통 및 Deltacron SARS-CoV-2 중화Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Antibody neutralization BNT162b2 BNT162b2 vaccine contribute convalescent sera dose evade geometric mean geometric mean titre geometric mean titres GMT GMTs highest Identifier immune immune evasion individual infected individual infected individuals Infection Mutation neutralization neutralization activity neutralized of BNT162b2 omicron post-dose SARS-CoV-2 SARS-CoV-2 spike sera titre Trial registration unique USA-WA1/2020 vaccinated individual Vaccine variant variants variants. [DOI] 10.1080/22221751.2022.2099305 PMC 바로가기 [Article Type] Article
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021Article Published on 2022-10-012022-11-15 Journal: Eurosurveillance [Category] COVID19(2023년), SARS, 진단, [키워드] antibody antibody level baseline characteristics body mass cardiovascular disease Chronic kidney disease chronic obstructive Comorbidity Concentration conducted congestive heart failure coronavirus COVID-19 COVID-19 vaccination COVID-19 vaccine cut-off diabete dose Factor female first dose geometric mean GFR glomerular filtration rate GMC GMCs IgG IgG antibodies IgG antibody Immunosuppression Infection Inflammatory bowel disease levels of antibody male mRNA Patient peaked pulmonary disease remained repeated reported resource retrospective cohort study SARS-CoV-2 SARS-CoV-2 spike serological serology solid malignancy the antibody the SARS-CoV-2 titre vaccination vaccination. were used [DOI] 10.2807/1560-7917.ES.2022.27.40.2100703 PMC 바로가기
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 studyClinical Trial Published on 2022-09-012022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% CI Administered Adults adverse event age all age group antibody baseline Bharat Biodefense children clinical conducted COVID-19 vaccine curtail deaths decrease demonstrated dose Efficacy eight eligible Endpoint enrolled female Fever for inclusion geometric mean GMT ratio GMTs group groups healthy children hospital Hyderabad immunogenicity immunosuppressive inactivated Inactivated vaccine India Infection injection site pain intramuscular dose less Local local reaction male Mild Mild-to-moderate multicentre neutralisation test neutralising antibody response neutralising antibody titre no difference Open-label Pain pandemic participant Phase 2 study phase 2/3 platform positive PRNT Reactions reactogenicity reduction Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine second dose Serious Adverse Events seroconverted serology test serum sample severity of COVID-19 susceptible Symptom three group titre Trial were excluded Withdrawal [DOI] 10.1016/S1473-3099(22)00307-3 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana projectArticle Published on 2022-08-292022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] adverse event age and sex analyzed anti-SARS-CoV-2 baseline Biomarker booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine chemiluminescence chemokines Concentration Controlled trial COVID-19 Cytokines death dose effective Effectiveness evaluated exclusion first dose Fractional dose Frequency geometric mean Growth factors healthcare worker Hospitalization immune response immunization immunoassay immunogenic immunogenicity incidence incidence rate increase in indicate individual individuals multiplex neutralizing antibody non-inferiority non-randomized plaque reduction neutralization plasma pre-immune primary endpoint PRNT Protein quantified RBD Receptor binding domain Registered reported RT-PCR Safe Safety second dose Serious Adverse Event seroconversion rate seronegative seropositive seropositive subject SUS Vaccine vaccine. Vaccines [DOI] 10.3389/fimmu.2022.966416 PMC 바로가기
Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection유사형 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 중화 항체 반응은 mRNA-1273과 BNT162b2 코로나바이러스 질병 2019(COVID-19) 백신과 SARS-CoV-2 감염의 역사에 따라 다릅니다.Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] 19 2 95% confidence interval Antibody titer BNT162b2 BNT162b2 vaccine calculated coronavirus 2 CoV COVID COVID-19 Dilution dose geometric mean GMT GMTs highest history increase Infection inhibitory linear mixed-effects models mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA-1273 mRNA-1273 vaccine NAb Neutralizing antibodies neutralizing antibodies. neutralizing antibody participant participants with SARS-CoV-2 prospective cohort pseudotype virus receiving respiratory response SARS SARS-CoV-2 SARS-COV-2 infection sera single dose Symptoms T Test tested uninfected participant uninfected participants vaccination Vaccine vaccine dose was collected [DOI] 10.1093/cid/ciab1038 PMC 바로가기 [Article Type] Article
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine RecipientsBNT162b2 또는 CoronaVac 백신 수혜자의 혈청에 의한 중증 급성 호흡기 증후군 코로나바이러스 2 오미크론 변이체의 중화Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antibody titer Antibody titers Beta Beta variant beta variants BNT162b2 CoronaVac coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta variants detectable Effectiveness elicited evade genome sequence geometric geometric mean GISAID database GMT GMTs Health Organization isolate Lineage Live virus microneutralization Mutation Nanopore nanopore sequencing neutralization Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer no significant difference not affect of BNT162b2 omicron Omicron variant Patient recipient recipients respiratory risk Risk assessment SARS-CoV-2 Sequencing sera severe acute respiratory syndrome Coronavirus significant difference significantly lower spike mutation strain Strains susceptibility TMPRSS2 Vaccine Vaccines variant Variant of concern. VeroE6 cells virus was determined whole genome sequence World Health Organization [DOI] 10.1093/cid/ciab1041 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial6세 이상의 건강한 참가자를 대상으로 한 상동 프라임-부스트 요법을 사용한 재조합 아데노바이러스 5형 벡터 코로나바이러스 질병 2019(COVID-19) 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 2b상 시험Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, 진단, 치료기술, [키워드] Ad5-vectored COVID-19 vaccine Adenovirus adenovirus type-5-vectored COVID-19 vaccine Adults Adverse adverse events antibody Antibody Response boost children clinical Cohort coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose double-blind elicited ELISA enrolled enzyme enzyme-linked immunosorbent assay event geometric mean geometric mean titer geometric mean titers GMT GMTs healthy homologous homologous prime immune response immune responses immunogenicity increasing age MIN neutralizing antibody participant phase phase 2b trial. Placebo placebo-controlled trial prime-boost regimen pseudovirus neutralizing antibody Randomized RBD receiving Receptor binding domain recombinant recombinant adenovirus robust Safe Safety SARS-CoV-2 single dose tolerable Trial vaccination Vaccine Viral viral particle [DOI] 10.1093/cid/ciab845 PMC 바로가기 [Article Type] Randomized Controlled Trial
A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers인간 혈장에서 항 바이러스 전구 약물 Molnupiravir의 결정을위한 검증 된 LC-MS/MS 방법 및 건강한 이집트 자원 봉사자들의 약동학 적 모델링 연구에 대한 적용Article Published on 2022-08-152022-08-31 Journal: Journal of chromatography. B, Analytical technolog [Category] COVID19(2023년), MERS, SARS, 치료기술, 치료제, [키워드] acetic acetic acid acetonitrile Agilent analyte analyzed Antiviral approach AUC C max Concentration confidence interval detection determine develop dosage dose Eclipse Efficacy ESI evaluate extraction FDA flow rate geometric mean geometric mean ratios Geometric means GMR Guidance healthy healthy volunteer healthy volunteers Human plasma LC-MS/MS Linear regression linearity m/z mass spectrometer mass spectrometry maximum concentration metabolite mixture molnupiravir N-hydroxycytidine NHC pharmacokinetic pharmacokinetic data plasma Population Population Pharmacokinetic Modeling positive protein precipitation pumped recommendation required ribavirin SARS-CoV-2 SARS-CoV-2. Simulation solvent subjects therapeutic target therapeutic targets Treatment triple quadrupole mass spectrometer United State United States Volunteer was performed was used were used [DOI] 10.1016/j.jchromb.2022.123363 PMC 바로가기 [Article Type] Article